for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

U.S. FDA approves Biogen Alzheimer's drug

June 7 (Reuters) - U.S. regulators on Monday approved Biogen Inc’s aducanumab as the first treatment to address an underlying cause of Alzheimer’s disease despite controversy over mixed clinical trial results for the drug. (Reporting By Deena Beasley in Los Angeles and Ankur Banerjee in Bengaluru; Editing by Shounak Dasgupta)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up